middle.news
How Neurizon’s NUZ-001 Extends ALS Survival by 16 Months
8:27pm on Friday 29th of August, 2025 AEST
•
Biotechnology
Read Story
How Neurizon’s NUZ-001 Extends ALS Survival by 16 Months
8:27pm on Friday 29th of August, 2025 AEST
Key Points
NUZ-001 safe and well-tolerated over 2.5 years at Phase 2 dose
Treatment linked to 76.7% reduced risk of death and ~16 months median survival extension
Slowed functional decline by 31% and respiratory decline by 43% versus historical controls
Supportive biomarker trends with stable plasma NfL and decreased urinary p75
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neurizon Therapeutics (ASX:NUZ)
OPEN ARTICLE